ZyVersa Therapeutics Reports New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/13/23
ZyVersa Therapeutics Adds Dr. Richard J. Glassock to Its Renal Scientific Advisory Board to Support Clinical Advancement of Renal Cholesterol Efflux Mediator™ VAR 200GlobeNewsWire • 03/07/23
ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare ConferenceGlobeNewsWire • 03/01/23
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual ConferenceGlobeNewsWire • 02/27/23
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer's Disease Following Traumatic Brain InjuryGlobeNewsWire • 02/23/23
ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/27/23
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch EventGlobeNewsWire • 01/11/23
ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200PRNewsWire • 01/03/23
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 41st Annual J.P.PRNewsWire • 12/20/22
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")PRNewsWire • 12/13/22